drugset / Trial / NCT04971031

A Clinical Trial to Assess Subjects With Dry Eye Disease.

NCT04971031

Phase 2 Completed 158 enrolled Aldeyra Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

Timeline

Start
2021-06-15
Primary completion
2021-09-08
Completion
2021-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Reproxalap Other / unclassified 0.25 % Other

Indications